Thomapyrin CLASSIC: over-the-counter pain relief in focus

Responsible: ad hoc news Flagship & Bestseller Desk. Reviewed prior to publication on June 15, 2026 at 10:45:50 AM ET. Details in the imprint.

Thomapyrin CLASSIC is an over-the-counter pain reliever marketed by Sanofi for short-term treatment of mild to moderate pain such as headaches and migraine attacks in adults and adolescents from 12 years of age. The tablets combine acetylsalicylic acid, paracetamol (acetaminophen) and caffeine in a fixed-dose formula that is designed to work faster and more effectively than acetylsalicylic acid alone. In Germany, Thomapyrin CLASSIC is typically sold in packs of 20 or 50 tablets, with street prices for a 20-tablet box often in the range of about €5 to €8 depending on pharmacy and promotions, while exact US-dollar prices vary with exchange rates and retailer pricing policies. The brand belongs to a long-established line of pain remedies in the German-speaking market and is part of Sanofi's consumer healthcare portfolio.

What Thomapyrin CLASSIC does and how it is formulated

According to the official German product information from Sanofi, each Thomapyrin CLASSIC tablet contains 250 mg acetylsalicylic acid (ASA), 250 mg paracetamol and 50 mg caffeine as active ingredients. The combination is indicated for short-term relief of acute mild to moderate pain, including headaches, toothache and menstrual pain, as well as for treating migraine attacks with or without aura in adults and adolescents 12 years and older who weigh at least 40 kg. Sanofi explains that the triple combination is intended to provide a broader mechanism of action: acetylsalicylic acid and paracetamol act as analgesics and antipyretics, while caffeine can enhance the pain-relieving effect and may accelerate onset of action in some patients.

On German-language consumer sites such as the official Thomapyrin page from Sanofi, the recommended dose for adults and adolescents from 12 years is typically one to two tablets taken with plenty of liquid, up to three times per day, with at least four hours between doses and a maximum of six tablets per day. The product is labeled for short-term use only, and users are instructed not to take the medicine for more than 3 days for fever or more than 4 days for pain without medical advice. Package labeling also highlights that Thomapyrin CLASSIC is not suitable for children under 12 years and must not be used in certain situations, for example in patients with known hypersensitivity to salicylates, a history of asthma attacks triggered by salicylates or other non-steroidal anti-inflammatory drugs (NSAIDs), active gastric or duodenal ulcers, or severe hepatic or renal impairment.

Sanofi's information further notes that, like other medicines containing acetylsalicylic acid, Thomapyrin CLASSIC should not be used in the last trimester of pregnancy and is not recommended during breast-feeding without medical supervision. The product information also warns against use in combination with other medicines that contain paracetamol or salicylates to avoid overdose. Patients who take anticoagulants, have a history of peptic ulcer disease, or suffer from chronic kidney or liver disease are advised to consult a physician before use. The label also mentions that caffeine may lead to sleep disturbances in sensitive individuals if taken close to bedtime.

From a formulation standpoint, Thomapyrin CLASSIC uses standard film-coated tablets that are designed to be swallowed whole with water. Inactive ingredients include cellulose, maize starch and other common tablet excipients, which make up the core and coating to ensure stability and ease of swallowing. Sanofi emphasizes in its consumer-facing materials that the product has been available in Germany for decades and is one of the best-known brands for tension headaches and migraine attacks in that market. Several German pharmacy portals list the brand among frequently recommended over-the-counter options for acute headache relief, alongside single-substance products containing only ibuprofen or paracetamol.

Headache societies and independent reviews in German-language health portals describe the combination of acetylsalicylic acid, paracetamol and caffeine as an evidence-based option for acute migraine treatment when used according to labeling. Published analyses referenced by these portals report that fixed-dose combinations of these three substances can be more effective than each component alone for some patients with migraine attacks, provided that dosage limits and contraindications are respected. Nonetheless, medical experts stress that combination analgesics should be used sparingly and that overuse can contribute to medication-overuse headaches, so guidance typically recommends limiting intake to no more than 10 days per month. Consumers are therefore encouraged to track how often they use such products and consult a healthcare professional if headaches become more frequent or severe.

According to Sanofi and German regulatory information, Thomapyrin CLASSIC is classified as a pharmacy-only medicine in Germany, which means it is sold without prescription but only through pharmacies, including online pharmacies that operate under German law. For US consumers, the product is not registered under the Thomapyrin brand name with the US Food and Drug Administration, and it is not marketed as a domestic over-the-counter product in US drugstores. However, the individual active ingredients acetylsalicylic acid, acetaminophen and caffeine are widely available in the United States in various branded and generic combination products for tension headaches and migraines. Some cross-border or online retailers offer Thomapyrin products that can be shipped internationally, but availability and legality can depend on local regulations, customs rules and labeling requirements in the destination country.

Price comparisons on German online pharmacy platforms show that Thomapyrin CLASSIC is often discounted from the recommended retail price, especially for larger pack sizes. Converted to US dollars, typical German internet pharmacy prices for a 20-tablet pack as of mid-2026 roughly equate to around $6 to $10, depending on the euro-dollar exchange rate and retailer-specific discounts. Actual prices for US-based buyers using cross-border options may differ because of shipping costs, taxes and import fees, and US consumers considering such purchases should check local rules and any limitations on importing medicinal products for personal use. As a general rule, people who want to use a combination product with acetylsalicylic acid, acetaminophen and caffeine have numerous domestically approved alternatives at US pharmacies and big-box retailers, often in both brand-name and store-brand versions.

From a portfolio perspective, Thomapyrin CLASSIC sits in Sanofi's consumer healthcare segment, which includes over-the-counter products for pain, allergy, digestive health and other everyday conditions. The Thomapyrin line also includes variants such as Thomapyrin INTENSIV and specific migraine formulations in some markets, with slightly different strengths or indications. In Germany and neighboring countries, the brand benefits from high recognition through longstanding advertising campaigns and presence in pharmacies, and it competes with other established pain-relief brands sold by multinational and regional manufacturers. For Sanofi, such over-the-counter pain remedies complement the company's larger prescription pharmaceutical and vaccines businesses by providing cash-generative brands with relatively stable demand patterns. In summary, Thomapyrin CLASSIC remains one of the recognizable OTC pain-relief options in its core markets, even though US consumers will more commonly encounter similar combinations under different local brand names.

Sanofi groups Thomapyrin within its broader consumer health strategy, which focuses on self-care brands and aims to grow in segments like pain, allergy and digestive wellness through targeted marketing and product line extensions. While the company does not regularly break out sales figures for individual OTC brands in public filings, pain-relief products are generally described as an important part of its European consumer portfolio. Shares of Sanofi S.A. (FR0000120578, ticker SNY) traded at $44.25 on Nasdaq on June 12, 2026.

This article was created with a.i. assistance and editorially reviewed. Product information is provided without warranty; prices and availability may change at any time. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.